Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp. is a commercial-stage healthcare company focused on immune medicine for disease diagnosis and treatment. The company has developed an immunosequencing platform that combines proprietary chemistry, computational biology, and machine learning to produce clinical immunomics data designed to better understand the adaptive immune system. Its commercial diagnostics include clonoSEQ, a test used to detect and monitor minimal residual disease in cancer patients during and after treatment. Adaptive Biotechnologies also provides products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company, formerly known as Adaptive TCR Corporation, adopted its current name in December 2011 and was incorporated in 2009. It is headquartered in Seattle, Washington, and its common stock trades on the NASDAQ under the symbol ADPT.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ADPT
|
$13.04
|
-41.4% Downside
|
Overvalued
|
$22
|
-1.1% Downside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
July 29, 2026
|
-70.9x
|
16.3x
|
11.9x
|
3.499 B
|
3.501 B
|
5.6%
|
78.5%
|
3.4
|
—
|
59.5%
|
